ライフサイエンスコーパス: phorbol 12-myristate 13-acetate

1 ment of exocytosis by the phorbol ester PMA (phorbol 12-myristate 13-acetate).

2 N-formyl-methionyl-leucyl-phenylalanine, or phorbol 12-myristate 13-acetate.

3 KCdelta downstream effectors ROCK and JNK by phorbol 12-myristate 13-acetate.

4 twice weekly application of proinflammatory phorbol 12-myristate 13-acetate.

5 , but was indispensable for such activity by phorbol 12-myristate 13-acetate.

6 hyperproduction of IL-6 in response to 4beta phorbol 12-myristate 13-acetate.

7 n a model of toxic contact eczema induced by phorbol 12-myristate 13-acetate.

8 cluding lipopolysaccharide, doxorubicin, and phorbol 12-myristate 13-acetate.

9 tion by LPA but not by fetal bovine serum or phorbol 12-myristate 13-acetate.

10 12-dimethylbenz[a]anthracene and promoted by phorbol 12-myristate 13-acetate.

11 zymosan and modestly reduced activity after phorbol 12-myristate 13-acetate.

12 ct the Shp2-independent Erk1/2 activation by phorbol 12-myristate 13-acetate.

13 xpressed high levels of CD28 when exposed to phorbol 12-myristate 13-acetate.

14 oxidative burst was preserved in response to phorbol 12-myristate 13-acetate.

15 arget genes, c-fos and egr-1, in response to phorbol 12-myristate 13-acetate.

16 lated cyclooxygenase-2 expression induced by phorbol 12-myristate-13-acetate.

17 ed after activation of protein kinase C with phorbol-12-myristate-13-acetate.

18 s oocytes by the protein kinase C activator, phorbol-12-myristate-13-acetate.

19 essin (100 and 500 pm) and the PKC activator phorbol 12-myristate 13-acetate (1 nm) each inhibited hu

20 ith (S730A)VACM-1/cul5 cDNA and treated with phorbol 12-myristate 13-acetate (10 and 100 nm) to induc

21 In a transmembrane invasion assay, phorbol-12-myristate-13-acetate (100 nmol/L) increased t

22 nteraction inhibitor, decreased 100 nm 4beta-phorbol 12-myristate 13-acetate (4beta-PMA)-induced co-i

23 Here, we show that 4beta-phorbol-12-myristate-13-acetate (4betaPMA), a stereosele

24 Phorbol 12-myristate 13-acetate (a PKC activator) had si

25 ERK1/2 are also activated in most cells by phorbol 12-myristate 13-acetate, a classical inhibitor o

26 ous inflammatory response that is induced by phorbol 12-myristate-13-acetate, a model of irritant con

27 In contrast, the phorbol ester PMA (phorbol-12-myristate-13-acetate, a pharmacological mimic

28 t of Vpr on monocyte-derived macrophages and phorbol 12-myristate 13-acetate-activated THP1 macrophag

29 1 is mobile on resting cells but immobile on phorbol-12-myristate-13-acetate-activated cells.

30 phosphorylation at Ser(430) is stimulated by phorbol 12-myristate 13-acetate, an activator of classic

31 as more prominent when NFAT was activated by phorbol 12-myristate 13-acetate and calcium ionophore io

32 Other ERK activators, phorbol 12-myristate 13-acetate and epidermal growth fac

33 r rottlerin prevented the effects induced by phorbol 12-myristate 13-acetate and human neutrophil ela

34 Phorbol 12-myristate 13-acetate and ionomycin stimulated

35 this effect is only detected following cell phorbol 12-myristate 13-acetate and ionomycin stimulatio

36 d could be bypassed through stimulation with phorbol 12-myristate 13-acetate and ionomycin.

37 x expression or in Jurkat cells treated with phorbol 12-myristate 13-acetate and ionomycin.

38 ficantly reduced NK- and T-cell responses to phorbol 12-myristate 13-acetate and ionomycin.

39 on of MEK and ERK following stimulation with phorbol 12-myristate 13-acetate and ionomycin.

40 , T-plastin-negative PBLs were stimulated by phorbol 12-myristate 13-acetate and ionomycin.

41 fG to the iNOS promoter could be enhanced by phorbol 12-myristate 13-acetate and suppressed by the pr

42 Isoproterenol also blocked ERK downstream of phorbol 12-myristate 13-acetate and the P2X(7) and epide

43 amma expression in response to ionomycin and phorbol 12-myristate 13-acetate and weakly enhanced expr

44 ls and NCI-H292 airway epithelial cells with phorbol 12-myristate 13-acetate and with human neutrophi

45 ecame phosphorylated at Ser27 in response to phorbol-12-myristate 13-acetate and this was prevented b

46 The stimulation of tissue with phorbol-12-myristate-13-acetate and ionomycin, recapitul

47 ulation by either anti-CD3 plus anti-CD28 or phorbol-12-myristate-13-acetate and ionomycin.

48 ) markedly enhanced superoxide production in phorbol 12-myristate 13-acetate - and fMet-Leu-Phe-stimu

49 chemical activators of shedding (ionomycin, phorbol 12-myristate 13-acetate, and 4-aminophenylmercur

50 The pharmacologic inhibitors chlorpromazine, phorbol 12-myristate 13-acetate, and cytochalasin D caus

51 nteractions among carbachol, PKC inhibitors, phorbol 12-myristate 13-acetate, and thapsigargin to mod

52 s most effective in preventing constitutive, phorbol 12-myristate 13-acetate-, and ionomycin-stimulat

53 Similar results were obtained with phorbol 12-myristate 13-acetate as well as activation of

54 y several microorganism membrane components, phorbol 12-myristate 13-acetate as well as by amyloid fi

55 dditive SERT inhibition by PD169316 and beta-phorbol 12-myristate 13-acetate (beta-PMA) indicated the

56 All PKDs are regulated by DAG/phorbol 12-myristate 13-acetate-binding C1 domains and a

57 lowed treatment of resident macrophages with phorbol 12-myristate 13-acetate, but treatment with lipo

58 Epidermal growth factor or the phorbol ester phorbol 12-myristate 13-acetate caused rapid phosphoryla

59 ecrosis factor alpha, lipopolysaccharide, or phorbol 12-myristate 13-acetate + CI.

60 tion induced by tumor necrosis factor (TNF), phorbol 12-myristate 13-acetate, cigarette smoke, okadai

61 tion of T cells with concanavalin A, but not phorbol 12-myristate 13-acetate combined with ionomycin,

62 implicate PKD1-Ser744 phosphorylation in the phorbol 12-myristate 13-acetate-dependent mechanism that

63 HL-60 cells treated with phorbol-12-myristate-13-acetate differentiate to a macro

64 ed macrophages, human monocytic THP-1 cells, phorbol 12-myristate 13-acetate-differentiated human mac

65 he inflammatory processes in THP-1 cells and phorbol-12-myristate-13-acetate-differentiated macrophag

66 lowing UVB or 7,12-dimethylbenz(a)anthracene/phorbol 12-myristate 13-acetate (DMBA/PMA) treatment dev

67 hat treatment with the inflammatory stimulus phorbol 12-myristate 13-acetate downregulates meprin alp

68 found that treatment with both ionomycin and phorbol 12-myristate 13-acetate ensured efficient nuclea

69 the role of cysteine string protein (csp) in phorbol-12-myristate-13-acetate-evoked cortical granule

70 Ionomycin and phorbol 12-myristate 13-acetate further increased the ac

71 r carcinogens and inflammatory stimuli (e.g. phorbol 12-myristate 13-acetate, H2O2, cigarette smoke c

72 on by serotonin showed a similar response to phorbol 12-myristate 13-acetate, implicating a potential

73 n cleavage of Pref-1 is markedly enhanced by phorbol 12-myristate 13-acetate in a dose- and time-depe

74 The apoptotic effect of phorbol 12-myristate 13-acetate in LNCaP cells was impai

75 ro and membrane translocation in response to phorbol 12-myristate 13-acetate in LNCaP cells.

76 o, with only marginal remaining activity for phorbol 12-myristate 13-acetate in vivo.

77 by the protein kinase C (PKC) activator PMA (phorbol 12-myristate 13-acetate) in Xenopus oocytes.

78 Phorbol 12-myristate 13-acetate increased intracellular

79 or rottlerin treatment versus activation by phorbol 12-myristate 13-acetate indicated that 2B15 unde

80 In contrast, phorbol 12-myristate 13-acetate induced low amplitude ca

81 Exposure of cells to 3 or 100 nM 4beta-phorbol 12-myristate-13-acetate induced co-immunoprecipi

82 increased relative basal and phorbol ester (phorbol 12-myristate 13-acetate)-induced PKC activity bu

83 )-induced PKC activity but were defective in phorbol 12-myristate 13-acetate-induced actin cytoskelet

84 ed proliferation, and provided resistance to phorbol 12-myristate 13-acetate-induced apoptosis in LNC

85 RNA (siRNA), and short hairpin RNA abrogated phorbol 12-myristate 13-acetate-induced down-regulation

86 ved GC synthesis protected skin from topical phorbol 12-myristate 13-acetate-induced inflammatory ass

87 s, and delayed apoptosis and cell death upon phorbol 12-myristate 13-acetate-induced Mk differentiati

88 lloproteinase-17 (ADAM17) is responsible for phorbol 12-myristate 13-acetate-induced release of TMEFF

89 The C1b domain mediates phorbol 12-myristate 13-acetate-induced translocation an

90 During phorbol-12-myristate 13-acetate-induced differentiation

91 -transformed B-cell lines partially restored phorbol-12-myristate-13-acetate-induced cell death.

92 subset of phenotypic changes that occur upon phorbol-12-myristate-13-acetate-induced differentiation

93 In addition, LeTx repressed phorbol-12-myristate-13-acetate-induced mouse mammary tu

94 protein kinase C (PKC) by the phorbol ester (phorbol 12-myristate 13-acetate) induces ceramide format

95 se mammary tumor virus promoter activity and phorbol 12-myristate 13-acetate induction of endogenous

96 cked by PKC inhibitors, unlike carbachol- or phorbol 12-myristate 13-acetate-initiated phosphorylatio

97 r cells were cultured unstimulated (U), with phorbol 12-myristate 13-acetate/ionomycin (PI) or lipopo

98 tokine production upon stimulation with both phorbol 12-myristate 13-acetate/ionomycin and CMV-peptid

99 ucers of p100 processing, but not by mitogen phorbol 12-myristate 13-acetate/ionomycin or cytokine tu

100 but also accelerated T cell activation under phorbol 12-myristate 13-acetate/ionomycin treatment cond

101 l activation through CD3/CD28 stimulation or phorbol 12-myristate 13-acetate/ionomycin treatment enha

102 s (mAbs), phytohaemagglutinin/interleukin-2, phorbol 12-myristate 13-acetate/ionomycin, prostratin, p

103 ic knockdown of GIMAP6 led to enhancement of phorbol 12-myristate 13-acetate/ionomycin-mediated activ

104 CPIP1 by MG132 abrogated HIV-1 production in phorbol 12-myristate 13-acetate/ionomycin-stimulated hum

105 lls were cultured overnight with and without phorbol 12-myristate 13-acetate/ionomycin.

106 Phorbol-12-myristate-13-acetate/ionomycin-induced MAPK s

107 Exogenously added diacylglycerol or phorbol 12-myristate 13-acetate, known activators of PKC

108 hibited NF-kappaB activation induced by TNF, phorbol 12-myristate 13-acetate, lipopolysaccharide, and

109 I, Ro-32-0432, Go6983, and Rottlerin, by the phorbol 12-myristate 13-acetate-mediated and time-depend

110 Conversely, the PKC agonist phorbol 12-myristate 13-acetate mimicked the Ang II effe

111 agents, such as cigarette smoke condensate, phorbol 12-myristate 13-acetate, okadaic acid, hydrogen

112 ibitory effect of AngII or the PKC activator phorbol 12-myristate 13-acetate on ROMK channels.

113 Moreover, enhancement of Egr-1 protein with phorbol 12-myristate 13-acetate or an egr-1 expression v

114 leasing peptide receptor treated with either phorbol 12-myristate 13-acetate or bombesin, respectivel

115 d PKCdelta (wild-type PKCdelta stimulated by phorbol 12-myristate 13-acetate or constitutively active

116 the activity of ADAM17, activated by either phorbol 12-myristate 13-acetate or EGF.

117 Upon stimulation with phorbol 12-myristate 13-acetate or fMet-Leu-Phe, p40(pho

118 Activation of PKCepsilon by phorbol 12-myristate 13-acetate or H(2)O(2) resulted in

119 Treatment of BMT or HSCT neutrophils with phorbol 12-myristate 13-acetate or rapamycin resulted in

120 lly increases in cardiomyocytes treated with phorbol 12-myristate 13-acetate or the alpha(1)-adrenerg

121 by N-formyl-methionyl-leucyl-phenylalanine, phorbol 12-myristate 13-acetate, or grass pollen allerge

122 low-density lipoprotein, 7-ketocholesterol, phorbol 12-myristate 13-acetate, or macrophage colony-st

123 uction of differentiation of thymocytes with phorbol 12-myristate 13-acetate plus ionomycin results i

124 ILC2s were then stimulated with phorbol 12-myristate 13-acetate plus ionomycin, IL-25 pl

125 reover, ILC2s expressed CD154 in response to phorbol 12-myristate 13-acetate plus ionomycin, IL-25/IL

126 ied a subset of CD8(+) T cells refractory to phorbol 12-myristate 13-acetate plus ionomycin-induced E

127 MB-231 and MDA-MB-435, upon stimulation with phorbol 12-myristate 13-acetate plus ionomycin.

128 Here, we show that phorbol 12 myristate 13-acetate (PMA) inhibited Ca2+ inf

129 Ionomycin and phorbol 12-myristate 13 acetate (PMA) are used to trigge

130 1 pre-monocyte macrophages (MDM) obtained by phorbol 12-myristate 13 acetate (PMA) treatment.

131 protein kinase Cepsilon (PKCepsilon), while phorbol 12-myristate 13-acetate (PMA) activation of PKCe

132 In contrast, C1a avidly ligated phorbol 12-myristate 13-acetate (PMA) and anchored DKF-1

133 mutant show enhanced ruffling in response to phorbol 12-myristate 13-acetate (PMA) and increased spee

134 nd produced IFN-gamma ex vivo in response to phorbol 12-myristate 13-acetate (PMA) and ionomycin stim

135 L-22 suppression, PP cells were treated with phorbol 12-myristate 13-acetate (PMA) and ionomycin, whi

136 fect of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) and PKC inhibitors

137 bol-13-acetate-type tumor promoters, such as phorbol 12-myristate 13-acetate (PMA) and teleocidin, in

138 Using phorbol 12-myristate 13-acetate (PMA) as a tool to disse

139 48-hour exposure to the potent PKC activator phorbol 12-myristate 13-acetate (PMA) at 10 nM concentra

140 nous NCX1 current (I(NaCa)) was increased by phorbol 12-myristate 13-acetate (PMA) but not by forskol

141 Activation of PKCs by phorbol 12-myristate 13-acetate (PMA) caused a redistrib

142 Although phorbol 12-myristate 13-acetate (PMA) caused limited tra

143 reatment of LNCaP prostate cancer cells with phorbol 12-myristate 13-acetate (PMA) causes a strong an

144 on-small cell lung cancer (NSCLC) cells with phorbol 12-myristate 13-acetate (PMA) during G1 phase in

145 d prevents activated platelet supernatant or phorbol 12-myristate 13-acetate (PMA) from inducing NETo

146 In this model, we show that phorbol 12-myristate 13-acetate (PMA) immediately activa

147 showed enhanced translocation in response to phorbol 12-myristate 13-acetate (PMA) in cells.

148 Activation of PKC with phorbol 12-myristate 13-acetate (PMA) in early G1 phase

149 Cells were also treated with phorbol 12-myristate 13-acetate (PMA) in the presence of

150 d selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-9

151 Treatment with the PKC activator phorbol 12-myristate 13-acetate (PMA) increased N-cadher

152 Phorbol 12-myristate 13-acetate (PMA) increased receptor

153 n the present study it was demonstrated that phorbol 12-myristate 13-acetate (PMA) induced PLD2 activ

154 In this study, we show that phorbol 12-myristate 13-acetate (PMA) is a potent stimul

155 nt with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) is known to protec

156 rect activation of PKC via the phorbol ester phorbol 12-myristate 13-acetate (PMA) mimics CXCL12-medi

157 that SOPD-Pep mitigated toxicity induced by phorbol 12-myristate 13-acetate (PMA) more effectively t

158 styryl dye imaging, we studied the effect of phorbol 12-myristate 13-acetate (PMA) on activity-depend

159 stigated the effects of PKC activation using phorbol 12-myristate 13-acetate (PMA) on hERG channels e

160 Potentiation of Ca(v) 2.3 currents by phorbol 12-myristate 13-acetate (PMA) or acetyl-beta-met

161 We show that treatment with a combination of phorbol 12-myristate 13-acetate (PMA) plus ionophore A23

162 lls, activation of protein kinase C by 4beta-phorbol 12-myristate 13-acetate (PMA) produced ceramide

163 Phorbol 12-myristate 13-acetate (PMA) promotes PKC delta

164 Phorbol 12-myristate 13-acetate (PMA) promotes skin canc

165 Treatment of astrocytes with phorbol 12-myristate 13-acetate (PMA) quickly and prefer

166 ith HIV (JLat cells) were more responsive to phorbol 12-myristate 13-acetate (PMA) reactivation in th

167 Exposure of cells expressing Nox5 to phorbol 12-myristate 13-acetate (PMA) resulted in a slow

168 The PKC activator phorbol 12-myristate 13-acetate (PMA) stimulated apoE se

169 Moreover, incubation of cells with phorbol 12-myristate 13-acetate (PMA) stimulated phospha

170 Interestingly, phorbol 12-myristate 13-acetate (PMA) stimulated phospho

171 CE), and this process is further enhanced by phorbol 12-myristate 13-acetate (PMA) stimulation.

172 Phorbol 12-myristate 13-acetate (PMA) switches on DKF-1

173 lastase (NE) release following activation by phorbol 12-myristate 13-acetate (PMA) than cells isolate

174 4 channels were inhibited by a PKC activator phorbol 12-myristate 13-acetate (PMA) through reduction

175 by collagenase digestion and incubated with phorbol 12-myristate 13-acetate (PMA) to activate PKC or

176 Phorbol 12-myristate 13-acetate (PMA) treatment resulted

177 l)maleim ide], or PKC depletion by prolonged phorbol 12-myristate 13-acetate (PMA) treatment, attenua

178 R) activity, in combination with IL-1beta or phorbol 12-myristate 13-acetate (PMA) treatment, results

179 In perforated-patch recordings, phorbol 12-myristate 13-acetate (PMA) up-regulated the c

180 studies with pharmacological agonists (e.g. phorbol 12-myristate 13-acetate (PMA)) indicate that pro

181 Indeed, phorbol 12-myristate 13-acetate (PMA), a direct activato

182 In the current work we used phorbol 12-myristate 13-acetate (PMA), a well recognized

183 cells were stimulated with thrombopoietin or phorbol 12-myristate 13-acetate (PMA), alphaIIbbeta3 bec

184 ion of the protein and by the phorbol ester, phorbol 12-myristate 13-acetate (PMA), an activator of p

185 However, following treatment with phorbol 12-myristate 13-acetate (PMA), ASP translocates

186 In addition, phorbol 12-myristate 13-acetate (PMA), but not 4alpha-PM

187 nduced by stimulation with the phorbol ester phorbol 12-myristate 13-acetate (PMA), but not by ionomy

188 ure to the protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA), enhanced TaALMT1-

189 nts or the protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA), in primary HUVECs

190 h the potent protein kinase C (PKC) agonist, phorbol 12-myristate 13-acetate (PMA), induces a transie

191 n kinase C activator, topical Ing3A, but not phorbol 12-myristate 13-acetate (PMA), inhibited the gro

192 Although bryostatin 1, like phorbol 12-myristate 13-acetate (PMA), is a potent activ

193 factor (TNF), interleukin-1beta (IL-1beta), phorbol 12-myristate 13-acetate (PMA), lipopolysaccharid

194 demonstrated that activation of PKCalpha by phorbol 12-myristate 13-acetate (PMA), or ectopic expres

195 ion with adenosine-5'-triphosphate (ATP) and phorbol 12-myristate 13-acetate (PMA), results in a cati

196 ith p38 kinase inducer, hydrogen peroxide or phorbol 12-myristate 13-acetate (PMA), U6 promoter activ

197 rogenase (LDH) isoforms after treatment with phorbol 12-myristate 13-acetate (PMA), which activates M

198 tubes were treated with the PKC/D1 activator phorbol 12-myristate 13-acetate (PMA), which acts as a D

199 factor CalDAG-GEFI inhibited SDF-1alpha- and phorbol 12-myristate 13-acetate (PMA)-induced adhesion t

200 ion of wild-type PKD3 in LNCaP cells blocked phorbol 12-myristate 13-acetate (PMA)-induced apoptosis

201 s revealed that, notably, androgens modulate phorbol 12-myristate 13-acetate (PMA)-induced apoptosis

202 ibition of NF-kappaB reversed both H2O2- and phorbol 12-myristate 13-acetate (PMA)-induced decrease i

203 in human myeloid HL-60 cells following their phorbol 12-myristate 13-acetate (PMA)-induced differenti

204 Here we studied the role of PK in phorbol 12-myristate 13-acetate (PMA)-induced megakaryoc

205 Ankrd1 deletion enhanced both basal and phorbol 12-myristate 13-acetate (PMA)-induced MMP13 prom

206 WASP expression blocked HCMV-induced but not phorbol 12-myristate 13-acetate (PMA)-induced monocyte m

207 vestigated the signalling pathway regulating phorbol 12-myristate 13-acetate (PMA)-induced MUC5AC gen

208 Both basal and phorbol 12-myristate 13-acetate (PMA)-induced NADPH oxid

209 Bryostatin 1 impairs phorbol 12-myristate 13-acetate (PMA)-induced tumor prom

210 nsfer (BRET), we detected a constitutive and phorbol 12-myristate 13-acetate (PMA)-induced ubiquitina

211 In addition, Dexras1 significantly reduced phorbol 12-myristate 13-acetate (PMA)-stimulated AC2 act

212 leukocyte protease profiles under naive and phorbol 12-myristate 13-acetate (PMA)-stimulated conditi

213 Phorbol 12-myristate 13-acetate (PMA)-stimulated PMNs ad

214 gh tyrosine phosphorylation in H(2)O(2)- and phorbol 12-myristate 13-acetate (PMA)-treated cardiomyoc

215 ator of conventional and novel PKC isoforms, phorbol 12-myristate 13-acetate (PMA).

216 ) was combined with human PMN induced with 4-phorbol 12-myristate 13-acetate (PMA).

217 7(phox) and activated Rac with activation by phorbol 12-myristate 13-acetate (PMA).

218 of MCF-7 cells with a potent PKC activator, phorbol 12-myristate 13-acetate (PMA).

219 We investigated cis elements regulated by phorbol 12-myristate 13-acetate (PMA).

220 isoforms by 24 h pretreatment of cells with phorbol 12-myristate 13-acetate (PMA).

221 sensitive or resistant to the tumor promoter phorbol 12-myristate 13-acetate (PMA).

222 was directly activated by the phorbol ester phorbol 12-myristate 13-acetate (PMA).

223 n the presence of inflammatory mediators and phorbol 12-myristate 13-acetate (PMA).

224 m untreated HeLa cells or cells treated with phorbol 12-myristate 13-acetate (PMA).

225 ld be achieved in mitotic cells treated with phorbol 12-myristate 13-acetate (PMA).

226 ty of RSK2 purified from cells stimulated by phorbol 12-myristate 13-acetate (PMA).

227 inhibitor, TAPI-1, while it was promoted by phorbol 12-myristate 13-acetate (PMA).

228 n PC1(lo) cells when stimulated with LPS and phorbol 12-myristate 13-acetate (PMA).

229 BACH2 expression resulted in suppression of phorbol 12-myristate 13-acetate (PMA)/ionomycin-driven a

230 ct on proinflammatory cytokine production of phorbol 12-myristate 13-acetate (PMA)/ionomycin-stimulat

231 Phorbol ester [phorbol 12-myristate 13-acetate (PMA)] treatment of huma

232 The PKC activator, phorbol 12-myristate 13-acetate (PMA, 0.5 microm) had no

233 e concurrently stimulated with 10% serum and phorbol 12-myristate 13-acetate (PMA, 100 nM), a potent

234 be modulated by treatment with anisomycin or phorbol 12-myristate 13-acetate (PMA/12-O-tetradecanoylp

235 PKC activation by phorbol 12-myristate 13-acetate (PMA; 100 nM; 30 minutes

236 le of putrescine, spermidine and spermine in phorbol 12-myristate-13-acetate (PMA)-induced macrophage

237 scriptional responses to the tumor promoter, phorbol-12-myristate 13-acetate (PMA), in cells with var

238 rt studies of HIF-1alpha induction following phorbol-12-myristate 13-acetate (PMA)-induced differenti

239 nels (Ca(v)) 2.2 currents are potentiated by phorbol-12-myristate, 13-acetate (PMA), whereas Ca(v) 2.

240 e (MCh), a muscarinic M1 receptor agonist or phorbol-12-myristate, 13-acetate (PMA).

241 iR-21 are induced by common stimuli, such as phorbol-12-myristate-13-acetate (PMA) and androgens, but

242 Human THP-1 monocytes were activated with phorbol-12-myristate-13-acetate (PMA) and differentiated

243 cells, the action of the PKC activator 4beta-phorbol-12-myristate-13-acetate (PMA) evokes ceramide fo

244 K562 chronic myelogenous leukemia cells with phorbol-12-myristate-13-acetate (PMA) induces megakaryoc

245 Treatment of cells with the PKC activator phorbol-12-myristate-13-acetate (PMA) potently stimulate

246 directly on-chip and free radical release by phorbol-12-myristate-13-acetate (PMA) stimulation was de

247 line that can be differentiated in vitro by phorbol-12-myristate-13-acetate (PMA) treatment to produ

248 isolated human monocytes pre-activated with phorbol-12-myristate-13-acetate (PMA) were added back in

249 bitor peptide and mimicked by application of phorbol-12-myristate-13-acetate (PMA), implicating a PKC

250 Phorbol-12-myristate-13-acetate (PMA)-induced mucin hype

251 -eta expressed correlates with the degree of phorbol-12-myristate-13-acetate (PMA)-induced proliferat

252 skin upon treatment with the tumor promoter phorbol-12-myristate-13-acetate (PMA).

253 or without UDCA and further activated using phorbol-12-myristate-13-acetate (PMA).

254 a by TCR-independent polyclonal stimulation (phorbol 12-myristate 13-acetate [PMA] plus ionomycin).

255 of AJH-836 and a prototypical phorbol ester (phorbol 12-myristate 13-acetate, PMA) to induce changes

256 and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.

257 2) depletion, whereas activation of PKC with phorbol-12-myristate-13-acetate potentiated the Ci-VSP-i

258 in and pertussis toxin but were abolished by phorbol 12-myristate 13-acetate pretreatment, suggesting

259 th the literature, at room temperature, PMA (phorbol 12-myristate 13-acetate) produced a large reprod

260 ressing PKCdelta followed by incubation with phorbol 12-myristate 13-acetate resulted in an increase

261 tive PKD or PKD activation by treatment with phorbol 12-myristate 13-acetate results in phosphorylati

262 CREB activation depends on a phorbol ester (phorbol 12-myristate 13-acetate)-sensitive protein kinas

263 We found that acute activation of PKC with phorbol 12-myristate 13-acetate shortened carbachol-evok

264 ound that activation of the PKC pathway with phorbol 12-myristate 13-acetate significantly increased

265 , or the PKCalpha-activator and TJ-disruptor phorbol-12-myristate-13-acetate, similarly reduced TJ in

266 Only SFHFKSGSL, in PKCdelta-transfected phorbol 12-myristate 13-acetate-stimulated cells, caused

267 ceptor-mediated IL-4 secretion but inhibited phorbol 12-myristate 13-acetate-stimulated IL-4 secretio

268 d reduced to alpha-ClFOH in both control and phorbol 12-myristate 13-acetate-stimulated neutrophils.

269 signal of O2[Symbol: see text] generated by phorbol 12-myristate 13-acetate-stimulated neutrophils.

270 the L-selectin tail with cell extracts from phorbol 12-myristate 13-acetate-stimulated Raw 264.7 mac

271 MMP-9 transcription was decreased in phorbol 12-myristate 13-acetate-stimulated THP-1 macroph

272 Phorbol 12-myristate 13-acetate stimulation of both cell

273 way in lymphocytes after antigen receptor or phorbol 12-myristate 13-acetate stimulation, whereas CD4

274 NA synthesis of CHRF cells in the absence of phorbol 12-myristate 13-acetate stimulation.

275 pidly phosphorylated at Ser31 in response to phorbol 12-myristate 13-acetate stimulation.

276 eceptor mimetic carbachol, the phorbol ester phorbol 12-myristate 13-acetate, the Ca(2+) ionophore io

277 tuitary tumor-derived cell line treated with phorbol-12-myristate-13-acetate; these results were conf

278 that addition of the NADPH oxidase activator phorbol 12-myristate 13-acetate to nitric oxide-producin

279 the expression of K-Rta or by treatment with phorbol 12-myristate 13-acetate (TPA) and/or n-butyrate.

280 The PKC agonist, phorbol 12-myristate 13-acetate (TPA, 100 nM, 4 h), indu

281 In contrast, phorbol 12-myristate-13-acetate (TPA) -induced cleavage

282 Whole rat lenses were treated with phorbol-12-myristate-13-acetate (TPA) to activate PKCgam

283 rmoset lymphoblastoid cells by phorbol ester phorbol-12-myristate-13-acetate (TPA).

284 signalling in lipin1 deficient myoblasts by phorbol 12-myristate 13-acetate transiently activated PK

285 kines IL-1beta and TNF-alpha were reduced in phorbol 12-myristate 13-acetate-treated MCs developed fr

286 more, 7E4 abrogated LFA-1/ICAM-1 adhesion of phorbol 12-myristate 13-acetate-treated MOLT-4 cells.

287 effect of conditioned medium collected after phorbol 12-myristate 13-acetate treatment could be inhib

288 esicle-like structures formed in response to phorbol 12-myristate 13-acetate treatment.

289 ele, and this differential is accentuated by phorbol 12-myristate 13-acetate treatment.

290 and insulinoma cells, either with or without phorbol 12-myristate 13-acetate treatment.

291 ent of pancreatoids with (-)-Indolactam-V or phorbol 12-myristate 13-acetate, two protein kinase C ac

292 i-T cell receptor (TCR) antibody without the phorbol 12-myristate 13-acetate usually used previously.

293 cation of PKCdelta to the plasma membrane by phorbol 12-myristate 13-acetate was enhanced in p23-depl

294 S) in response to angiotensin II (Ang II) or phorbol 12-myristate 13-acetate was markedly reduced in

295 th platelet activating factor, ionomycin, or phorbol 12-myristate 13-acetate was significantly enhanc

296 The increases by strain, PGE2, Wnt-3a, and phorbol 12-myristate 13-acetate were attenuated by inhib

297 PKC, experiments with the PKC activator PMA (phorbol 12-myristate 13-acetate) were performed.

298 selectively prevents nPKCdelta depletion by phorbol 12-myristate 13-acetate when coapplied, coincide

299 NFAT1 upon co-stimulation with ionomycin and phorbol 12-myristate 13-acetate, whereas anergic transcr

300 kinase C activation with the phorbol ester, phorbol 12-myristate 13-acetate, which has also been sho